

# Torsten Pietsch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7546298/publications.pdf>

Version: 2024-02-01

86  
papers

9,368  
citations

117625

34  
h-index

79698

73  
g-index

87  
all docs

87  
docs citations

87  
times ranked

10114  
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
2	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015, 27, 728-743.	16.8	933
3	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. <i>Acta Neuropathologica</i> , 2012, 123, 473-484.	7.7	863
4	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
5	International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading. <i>Brain Pathology</i> , 2014, 24, 429-435.	4.1	499
6	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA09): a randomised, open-label, phase 3 trial. <i>Lancet</i> , 2019, 393, 678-688.	13.7	384
7	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2927-2935.	1.6	381
8	cIMPACTNOW update 6: new entity and diagnostic principle recommendations of the cIMPACTNOW meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020, 30, 844-856.	4.1	363
9	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. <i>Acta Neuropathologica</i> , 2013, 125, 913-916.	7.7	244
10	Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. <i>Journal of Negative Results in BioMedicine</i> , 2011, 10, 7.	1.4	239
11	Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. <i>Neuro-Oncology</i> , 2012, 14, 1265-1284.	1.2	213
12	Optimization of Quantitative MGMT Promoter Methylation Analysis Using Pyrosequencing and Combined Bisulfite Restriction Analysis. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 368-381.	2.8	194
13	Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. <i>Neuro-Oncology</i> , 2018, 20, 123-131.	1.2	184
14	A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. <i>European Journal of Cancer</i> , 2015, 51, 522-532.	2.8	161
15	Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. <i>Cancer Cell</i> , 2018, 33, 829-842.e5.	16.8	140
16	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. <i>Acta Neuropathologica</i> , 2018, 136, 239-253.	7.7	118
17	A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (>16years) low grade glioma – A final report. <i>European Journal of Cancer</i> , 2017, 81, 206-225.	2.8	104
18	Supratentorial ependymomas of childhood carry C11orf95-RELA fusions leading to pathological activation of the NF- $\kappa$ B signaling pathway. <i>Acta Neuropathologica</i> , 2014, 127, 609-611.	7.7	103

#	ARTICLE	IF	CITATIONS
19	Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: A prospective observational multicentre study. <i>European Journal of Cancer</i> , 2013, 49, 893-903.	2.8	84
20	High frequency of H3F3A K27M mutations characterizes pediatric and adult high-grade gliomas of the spinal cord. <i>Acta Neuropathologica</i> , 2015, 130, 435-437.	7.7	83
21	Childhood supratentorial ependymomas with <i>YAP1</i> – <i>MAMLD1</i> fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. <i>Brain Pathology</i> , 2019, 29, 205-216.	4.1	75
22	Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. <i>Neuro-Oncology</i> , 2016, 18, 919-927.	1.2	68
23	Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1602-1616.	10.7	67
24	H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?. <i>Journal of Neuro-Oncology</i> , 2013, 112, 67-72.	2.9	65
25	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. <i>Neuro-Oncology</i> , 2018, 20, 1616-1624.	1.2	65
26	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 2028-2040.	1.6	58
27	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). <i>Neuro-Oncology</i> , 2018, 20, 400-410.	1.2	56
28	EANO–EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. <i>Lancet Oncology</i> , The, 2019, 20, e715-e728.	10.7	56
29	Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. <i>Brain Pathology</i> , 2019, 29, 325-335.	4.1	55
30	Update on the integrated histopathological and genetic classification of medulloblastoma – a practical diagnostic guideline. , 2016, 35, 344-352.		54
31	SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma. <i>Klinische Padiatrie</i> , 2019, 231, 107-135.	0.6	52
32	Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial. <i>Oncotarget</i> , 2015, 6, 38827-38839.	1.8	51
33	Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 791-797.	1.7	50
34	HGNET-BCOR Tumors of the Cerebellum. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1254-1260.	3.7	49
35	Impact of chemotherapy on disseminated low-grade glioma in children and adolescents: Report from the HIT–CGG 1996 trial. <i>Pediatric Blood and Cancer</i> , 2011, 56, 1046-1054.	1.5	47
36	Supratentorial ependymoma in childhood: more than just RELA or YAP. <i>Acta Neuropathologica</i> , 2021, 141, 455-466.	7.7	37

#	ARTICLE	IF	CITATIONS
37	Children &lt;1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: A report from the german multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG). <i>Pediatric Blood and Cancer</i> , 2014, 61, 457-463.	1.5	36
38	Strategies to improve the quality of survival for childhood brain tumour survivors. <i>European Journal of Paediatric Neurology</i> , 2015, 19, 619-639.	1.6	36
39	High-Resolution Genomic Analysis Does Not Qualify Atypical Plexus Papilloma as a Separate Entity Among Choroid Plexus Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 110-120.	1.7	31
40	Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. <i>EBioMedicine</i> , 2020, 59, 102962.	6.1	31
41	CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. <i>Acta Neuropathologica</i> , 2020, 140, 405-407.	7.7	30
42	MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma. <i>Clinical Neuroradiology</i> , 2019, 29, 595-604.	1.9	26
43	Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. <i>Clinical Epigenetics</i> , 2020, 12, 94.	4.1	26
44	Pediatric ependymoma: an overview of a complex disease. <i>Child's Nervous System</i> , 2021, 37, 2451-2463.	1.1	26
45	Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 1885-1897.	1.2	23
46	CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1781-1788.	4.2	22
47	Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features – a retrospective analysis of the HIT ependymoma trial cohort. <i>Acta Neuropathologica Communications</i> , 2019, 7, 181.	5.2	21
48	Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide. <i>Cancers</i> , 2019, 11, 858.	3.7	20
49	Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. <i>Oncologist</i> , 2019, 24, e921-e929.	3.7	19
50	Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low-grade glioma patients – Report from the German <sc>SIOP</sc> LGG 2004 cohort. <i>International Journal of Cancer</i> , 2020, 147, 3471-3489.	5.1	19
51	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. <i>Neuro-Oncology</i> , 2021, 23, 1012-1023.	1.2	19
52	A Global View on the Availability of Methods and Information in the Neuropathological Diagnostics of CNS Tumors: Results of an International Survey Among Neuropathological Units. <i>Brain Pathology</i> , 2016, 26, 551-554.	4.1	16
53	Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification. <i>PLoS ONE</i> , 2017, 12, e0178351.	2.5	15
54	Early Wound Site Seeding in a Patient with Central Nervous System High-Grade Neuroepithelial Tumor with BCOR Alteration. <i>World Neurosurgery</i> , 2018, 116, 279-284.	1.3	14

#	ARTICLE	IF	CITATIONS
55	Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 659-670.	2.5	14
56	Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome. <i>Child's Nervous System</i> , 2020, 36, 2693-2700.	1.1	14
57	Dysembryoplastic Neuroepithelial Tumor of the Septum Pellucidum and the Supratentorial Midline. <i>American Journal of Surgical Pathology</i> , 2016, 40, 806-811.	3.7	13
58	Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. <i>Acta Neuropathologica</i> , 2021, 142, 873-886.	7.7	12
59	Case of the month 1-2019: CNS high-grade neuroepithelial tumor with BCOR alteration. , 2019, 38, 4-7.		11
60	<sc><i>MGMT</i></sc> promoter methylation analysis for allocating combined <sc>CCNU</sc>/<sc>TMZ</sc> chemotherapy: Lessons learned from the <sc>CeTeG</sc>/<sc>NOA</sc>â€œ09 trial. <i>International Journal of Cancer</i> , 2021, 148, 1695-1707.	5.1	11
61	Evaluation of dose, volume, and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study. <i>Neuro-Oncology</i> , 2022, 24, 1193-1202.	1.2	11
62	Telomerase reverse transcriptase promoter mutationâ€œ and O6-methylguanine DNA methyltransferase promoter methylationâ€œmediated sensitivity to temozolomide in isocitrate dehydrogenaseâ€œwild-type glioblastoma: is there a link?. <i>European Journal of Cancer</i> , 2021, 147, 84-94.	2.8	10
63	Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial. <i>Neuro-Oncology</i> , 2022, 24, 127-137.	1.2	9
64	High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): management strategies and results from the German LGG study group. <i>Neuro-Oncology</i> , 2021, 23, 1148-1162.	1.2	9
65	Prognostic impact of distinct genetic entities in pediatric diffuse glioma <sc>WHO</sc>â€œgrade <sc>II</sc>â€œReport from the German/Swiss <sc>SIOPâ€œLGG</sc> 2004 cohort. <i>International Journal of Cancer</i> , 2020, 147, 2159-2175.	5.1	8
66	Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3ÂK27M Mutant Diffuse Midline Glioma. <i>Clinical Neuroradiology</i> , 2022, 32, 249-258.	1.9	8
67	Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status. <i>Pharmaceuticals</i> , 2021, 14, 195.	3.8	7
68	Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 419-430.	1.7	7
69	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. <i>Journal of Neuro-Oncology</i> , 2021, 155, 193-202.	2.9	6
70	Medulloblastoma with extensive nodularity: a tumour exclusively of infancy?. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 267-270.	3.2	5
71	No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany. <i>BMC Cancer</i> , 2021, 21, 526.	2.6	3
72	Pediatric high-grade gliomas and the WHO CNS Tumor Classificationâ€œPerspectives of pediatric neuro-oncologists and neuropathologists in light of recent updates. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	3

#	ARTICLE	IF	CITATIONS
73	Transitioning to molecular diagnostics in pediatric high-grade glioma: experiences with the 2016 WHO classification of CNS tumors. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab113.	0.7	2
74	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. <i>Journal of Neuro-Oncology</i> , 2022, 157, 37-48.	2.9	2
75	Chemotherapy for adult patients with spinal cord gliomas. <i>Neuro-Oncology Practice</i> , 2021, 8, 475-484.	1.6	1
76	ETMR-14. TREATMENT OF EMBRYONAL TUMOURS WITH MULTILAYERED ROSETTES (ETMR) WITH CARBOPLATIN-ETOPOSIDE INDUCTION AND TANDEM HIGH-DOSE CHEMOTHERAPY WITHIN THE PROSPECTIVE HIT-TRIALS AND REGISTRIES. <i>Neuro-Oncology</i> , 2020, 22, iii325-iii326.	1.2	1
77	EPEN-39. CLINICAL STRATIFIED TREATMENT OF LOCALIZED PEDIATRIC INTRACRANIAL EPENDYMOMA WITH COMBINED LOCAL IRRADIATION AND CHEMOTHERAPY WITHIN THE PROSPECTIVE, MULTICENTER E-HIT TRIAL " THE MOLECULAR SUBGROUP MATTERS. <i>Neuro-Oncology</i> , 2020, 22, iii315-iii316.	1.2	1
78	Radiotherapy and olaptesed pegol (NOX-A12) in partially resected or biopsy-only MGMT-unmethylated glioblastoma: Interim data from the German multicenter phase 1/2 GLORIA trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2050-2050.	1.6	1
79	EPEN-09. IMPACT OF MOLECULAR SUBGROUP ON OUTCOME FOR INFANTS &lt;12 MONTHS WITH INTRACRANIAL EPENDYMOMA - GERMAN EXPERIENCE FROM HIT2000, INTERIM-2000-REGISTRY AND I-HIT-MED REGISTRY. <i>Neuro-Oncology</i> , 2020, 22, iii309-iii309.	1.2	0
80	QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA " RESULTS OF THE HIT2000 TRIAL. <i>Neuro-Oncology</i> , 2020, 22, iii433-iii433.	1.2	0
81	MBCL-09. ISOLATED M1 METASTASES IN PEDIATRIC MEDULLOBLASTOMA: IS POSTOPERATIVE RADIOTHERAPY FOLLOWED BY MAINTENANCE CHEMOTHERAPY SUPERIOR TO POSTOPERATIVE SANDWICH-CHEMOTHERAPY AND RADIOTHERAPY?. <i>Neuro-Oncology</i> , 2020, 22, iii389-iii389.	1.2	0
82	BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi11-vi11.	1.2	0
83	CTNI-43. CXCL12 INHIBITION IN MGMT UNMETHYLATED GLIOBLASTOMA " RESULTS OF AN EARLY PROOF-OF-CONCEPT ASSESSMENT IN THE MULTICENTRIC PHASE I/II GLORIA TRIAL (NCT04121455). <i>Neuro-Oncology</i> , 2021, 23, vi69-vi69.	1.2	0
84	Molecular pathological insights reveal a high number of unfavorable risk patients among children treated for medulloblastoma and CNS"PNET in Oslo 2005"2017. <i>Pediatric Blood and Cancer</i> , 2022, , e29736.	1.5	0
85	MEDB-51. Impact of residual tumor on outcomes in children and adolescents with medulloblastoma in the German HIT-cohort. <i>Neuro-Oncology</i> , 2022, 24, i118-i118.	1.2	0
86	MEDB-37. Chemotherapy response prediction by molecular risk factors in metastatic childhood medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i113-i113.	1.2	0